---
title: "Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results"
date: 2022-03-01
publishDate: 2022-05-31T17:48:50.195757Z
authors: ["Jonathan I. Silverberg", "Marjolein de Bruin-Weller", "Thomas Bieber", "Weily Soong", "Kenji Kabashima", "Antonio Costanzo", "David Rosmarin", "Charles Lynde", "John Liu", "Amy Gamelli", "Jiewei Zeng", "Barry Ladizinski", "Alvina D. Chu", "Kristian Reich"]
publication_types: ["2"]
abstract: ""
featured: false
publication: "*Journal of Allergy and Clinical Immunology*"
tags: ["-100", "-75", "-90", "≥75%", "≥90%", "100%", "AD", "Adverse event", "AE", "Atopic dermatitis", "BE", "Blinded extension", "Coronavirus disease 2019", "COVID-19", "CPK", "Creatine phosphokinase", "EASI", "EASI-50", "Eczema Area and Severity Index", "Herpes zoster", "HZ", "Improvement from baseline in EASI of ≥50%", "JAK", "Janus kinase", "Janus kinase inhibitors", "Least squares mean", "LSM", "MI", "Multiple imputation", "Nonresponse imputation incorporating MI to handle missing data due to COVID-19", "NRI-C", "Patient-year", "PBO", "Placebo", "PY", "RA", "randomized clinical trial", "Rheumatoid arthritis", "TCS", "TEAE", "Topical corticosteroid", "topical corticosteroids", "Treatment-emergent adverse event", "upadacitinib", "Validated Investigator’s Global Assessment for AD of clear or almost clear with ≥2 grades of improvement", "vIGA-AD 01", "Worst Pruritus Numerical Rating Scale", "WP-NRS"]
url_pdf: "https://www.jacionline.org/article/S0091-6749(21)01212-4/fulltext"
doi: "10.1016/j.jaci.2021.07.036"
---

